Stock listing
NASDAQ:LIMN Liminatus Pharma, Inc. Stock
Home listing (NASDAQ) of Liminatus Pharma, Inc.
Follow Liminatus Pharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LIMN
$2.51 USD -0.17 (-6.3%)
Close on Nov 20, 2026
- Day range
- $2.51 – $2.99 USDNov 20, 2026
- Volume
- 61,860 sharesNov 20, 2026
- Market cap
- $3.37M USDAt the close on Nov 20, 2026 · price × 1.34M shares outstanding
- 52-week range
- $2.40 – $141.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $112,830 USDMedian day 23,146 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LIMN · Home | $2.51 USD | -0.17 (-6.3%) | 61,860 | $2.869 | $2.985 | $2.51 | $2.68 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LIMN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.51 | -0.17 | -6.3% | $2.869 | $2.985 | $2.51 | 61,860 | |
| $2.68 | -0.13 | -4.6% | $2.90 | $2.94 | $2.68 | 23,146 | |
| $2.81 | -0.16 | -5.4% | $2.98 | $3.05 | $2.80 | 22,764 | |
| $2.97 | -0.02 | -0.7% | $3.125 | $3.13 | $2.92 | 31,568 | |
| $2.99 | +0.22 | +7.9% | $2.907 | $2.99 | $2.805 | 13,223 | |
| $2.77 | -0.17 | -5.8% | $3.04 | $3.04 | $2.77 | 9,902 | |
| $2.94 | +0.17 | +6.1% | $2.979 | $3.075 | $2.85 | 27,220 | |
| $2.77 | +0.06 | +2.2% | $2.80 | $2.91 | $2.76 | 19,358 | |
| $2.71 | +0.17 | +6.7% | $2.56 | $2.825 | $2.56 | 19,678 | |
| $2.54 | -0.09 | -3.4% | $2.73 | $2.855 | $2.50 | 31,621 | |
| $2.63 | -0.164 | -5.9% | $2.91 | $3.07 | $2.60 | 104,742 | |
| $2.794 | +0.004 | +0.2% | $2.875 | $2.95 | $2.66 | 33,652 | |
| $2.79 | +0.27 | +10.7% | $2.63 | $2.83 | $2.404 | 44,854 | |
| $2.52 | -0.30 | -10.6% | $2.97 | $2.97 | $2.52 | 23,274 | |
| $2.82 | -0.075 | -2.6% | $2.98 | $3.00 | $2.75 | 12,963 | |
| $2.895 | -0.025 | -0.9% | $3.06 | $3.14 | $2.81 | 28,056 | |
| $2.92 | +0.03 | +1.0% | $3.106 | $3.106 | $2.92 | 10,996 | |
| $2.89 | -0.27 | -8.5% | $3.01 | $3.01 | $2.785 | 24,113 | |
| $3.16 | +0.22 | +7.5% | $3.05 | $3.245 | $2.96 | 9,366 | |
| $2.94 | -0.17 | -5.5% | $3.10 | $3.17 | $2.905 | 20,700 | |
| $3.11 | -0.01 | -0.3% | $3.19 | $3.24 | $3.10 | 12,800 | |
| $3.12 | -0.10 | -3.1% | $3.26 | $3.455 | $3.04 | 118,800 | |
| $3.22 | +0.11 | +3.5% | $3.285 | $3.295 | $3.05 | 33,000 | |
| $3.11 | +0.07 | +2.3% | $3.175 | $3.285 | $3.08 | 33,000 | |
| $3.04 | -0.17 | -5.3% | $3.30 | $3.30 | $3.01 | 17,100 | |
| $3.21 | -0.04 | -1.2% | $3.295 | $3.364 | $3.21 | 15,800 | |
| $3.25 | -0.16 | -4.7% | $3.50 | $3.55 | $3.25 | 20,100 | |
| $3.41 | -0.04 | -1.2% | $3.625 | $3.625 | $3.41 | 13,700 | |
| $3.45 | -0.31 | -8.2% | $3.70 | $3.82 | $3.40 | 28,800 | |
| $3.76 | +0.07 | +1.9% | $3.555 | $3.81 | $3.555 | 16,900 | |
| $3.69 | -0.19 | -4.9% | $3.95 | $3.95 | $3.531 | 38,600 | |
| $3.88 | +0.18 | +4.9% | $3.701 | $3.89 | $3.65 | 22,900 | |
| $3.70 | -0.29 | -7.3% | $3.95 | $3.95 | $3.69 | 12,500 | |
| $3.99 | +0.09 | +2.3% | $3.80 | $4.08 | $3.80 | 18,000 | |
| $3.90 | +0.15 | +4.0% | $3.75 | $3.95 | $3.75 | 24,300 | |
| $3.75 | +0.02 | +0.5% | $3.74 | $3.86 | $3.65 | 28,200 | |
| $3.73 | -0.18 | -4.6% | $3.81 | $3.974 | $3.71 | 9,100 | |
| $3.91 | -0.36 | -8.4% | $4.23 | $4.31 | $3.83 | 38,400 | |
| $4.27 | +0.075 | +1.8% | $4.14 | $4.479 | $4.13 | 18,500 | |
| $4.195 | +0.015 | +0.4% | $4.26 | $4.34 | $4.091 | 17,700 | |
| $4.18 | +0.15 | +3.7% | $4.16 | $4.23 | $4.00 | 16,800 | |
| $4.03 | -0.04 | -1.0% | $4.05 | $4.137 | $3.90 | 17,200 | |
| $4.07 | +0.43 | +11.8% | $3.71 | $4.26 | $3.641 | 88,300 | |
| $3.64 | +0.16 | +4.6% | $3.68 | $3.72 | $3.56 | 16,000 | |
| $3.48 | +0.09 | +2.7% | $3.43 | $3.675 | $3.41 | 23,100 | |
| $3.39 | +0.06 | +1.8% | $3.35 | $3.44 | $3.345 | 8,900 | |
| $3.33 | -0.18 | -5.1% | $3.46 | $3.545 | $3.32 | 15,300 | |
| $3.51 | -0.01 | -0.3% | $3.50 | $3.58 | $3.415 | 14,000 | |
| $3.52 | +0.05 | +1.4% | $3.45 | $3.615 | $3.29 | 38,000 | |
| $3.47 | -0.16 | -4.4% | $3.63 | $3.675 | $3.46 | 31,400 | |
| $3.63 | +0.15 | +4.3% | $3.54 | $3.80 | $3.451 | 19,000 | |
| $3.48 | -0.14 | -3.9% | $3.60 | $3.65 | $3.48 | 20,800 | |
| $3.62 | -0.09 | -2.4% | $3.72 | $3.725 | $3.52 | 26,300 | |
| $3.71 | +0.01 | +0.3% | $3.70 | $3.82 | $3.65 | 23,200 | |
| $3.70 | -0.14 | -3.6% | $3.64 | $3.91 | $3.61 | 22,500 | |
| $3.84 | +0.195 | +5.3% | $3.86 | $4.00 | $3.70 | 31,600 | |
| $3.645 | -0.215 | -5.6% | $3.80 | $3.80 | $3.42 | 53,200 | |
| $3.86 | -0.37 | -8.7% | $4.24 | $4.26 | $3.80 | 51,300 | |
| $4.23 | -0.17 | -3.9% | $4.36 | $4.74 | $4.23 | 38,700 | |
| $4.40 | -0.01 | -0.2% | $4.37 | $4.88 | $4.37 | 51,800 | |
| $4.41 | -0.20 | -4.3% | $4.42 | $4.545 | $4.26 | 49,100 | |
| $4.61 | -0.06 | -1.3% | $4.64 | $4.84 | $4.35 | 73,212 | |
| $4.67 | -0.49 | -9.5% | $5.03 | $5.04 | $4.61 | 83,117 | |
| $5.16 | -0.47 | -8.3% | $5.53 | $5.876 | $5.15 | 117,361 | |
| $5.63 | +0.045 | +0.8% | $5.69 | $5.945 | $5.395 | 1,431 |
Splits
1 split · NASDAQ:LIMN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation |
- Ticker
- NASDAQ:LIMN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Sep 29, 2026
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Latest news
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Sep 29, 2026
Closed $3.91 (-8.4%) on Sep 29, 2026
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Aug 24, 2026
Closed $4.67 (-9.5%) on Aug 24, 2026
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Aug 18, 2026
Closed $5.59 (-14.1%) on Aug 19, 2026
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Aug 13, 2026
Closed $7.50 (+38.2%) on Aug 13, 2026
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Jun 3, 2026
Closed $7.59 (-22.2%) on Jun 3, 2026
Liminatus Pharma Announces Nasdaq Delisting Notification
May 21, 2026
Closed $8.47 (-31.1%) on May 22, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Mar 17, 2026
Closed $11.50 (-2.5%) on Mar 17, 2026
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Feb 17, 2026
Closed $12.81 (-31.9%) on Feb 17, 2026
Liminatus Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 18 in all · newest Sep 29, 2026 · oldest 2022
- Decks
- 1 deck · latest Jun 24, 2025
Where Liminatus Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LIMN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LIMN | BOATS | United States | USD |
Valuation
Price/book 11.2× against a median of 0.7×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.80M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 11.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 4.8×
- Beta vs S&P 500
- 0.94
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Biotron Limited · ASX:BIT | US$3.70M | US$2.66M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPH | US$3.68M | −US$13.77M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.57 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,079 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX | US$3.19M | −US$12.81M | n/a | −12.8× | n/a | 0.2× | n/a | 0.0× | 1.54 |
| Azitra Inc · AMEX:AZTR | US$3.13M | −US$618,677 | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.60 |
| NuCana plc · NASDAQ:NCNA | US$3.12M | −US$21.39M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.58 |
| Revive Therapeutics Ltd. · CSE:RVV | US$3.10M | US$3.14M | n/a | n/a | n/a | n/a | n/a | n/a | 0.56 |
| Skye Bioscience, Inc. · NASDAQ:SKYE | US$3.10M | −US$1.71M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 0.85 |
| Median of the others | US$3.20M | −US$2.12M | −0.8× | 0.7× | −123.7% | 0.0× | 1.16 |
Team and board
| Officer | Role |
|---|---|
| Chris Kim | CEO |
Events
- Next results
- Nov 26, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 14, 2026 | −5.7% |
| Q3 2025 | Oct 6, 2025 | −8.7% |
| Q1 2025 | Apr 16, 2025 | |
| Q1 2023 | Apr 18, 2023 | −0.9% |
| Q3 2022 | Nov 21, 2022 | −0.1% |
| Q2 2022 | Aug 19, 2022 | −0.1% |
| Q1 2022 | Apr 18, 2022 | −0.2% |
| Q3 2021 | Nov 22, 2021 | −0.1% |
| Quarter to Jun 30, 2021 | Jul 22, 2021 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2025) | Investor deck | 22 slides | Jun 24, 2025 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or pre-funded warrants) and accompanying warrants Announced: about US$4M · US$0.29 a share · Warrants at US$0.29 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives | Feb 17, 2026 |
| Strategic investment of newly issued shares Announced: US$30M Buyers: Capital Trust Group Limited (USD 30,000,000 equity financing via subscription for newly issued shares) Use of proceeds: Research and development of advanced immunotherapy assets | Oct 30, 2025 |
| Not stated Announced: up to US$500M · Digital Offering Dealers: Digital Offering (lead) Use of proceeds: Acquisition and long-term holding of BNB Coin through the planned American BNB Strategy subsidiary | Jul 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | |
| Research and development | 0 | 2.69M | 3.76M | 1.85M | 3.80M |
| Selling, general and administrative | 2.97M | 645.0K | 1.06M | 856.0K | 197.0K |
| Operating income | -2.97M | -3.33M | -2.59M | -2.71M | -2.53M |
| Depreciation and amortization | 1.83K | 0 | 1.00K | ||
| EBITDA | -2.97M | -3.33M | -2.71M | ||
| Interest expense | 215.9K | 338.9K | 175.0K | 219.0K | |
| Income before tax | -10.2M | -2.89M | -1.19M | -2.93M | 4.37M |
| Income tax | 18.8K | 34.0K | 539.8K | ||
| Net income | -10.2M | -3.55M | -1.23M | -2.93M | 4.37M |
| Earnings per share, basic | -0.43 | -0.20 | -7.65 | -4.25 | 6.33 |
| Earnings per share, diluted | -0.43 | -0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 337.7K | 56.3K | 434.0K | 5.05M | 336.2K |
| Receivables | 6.46K | 945.0K | 100.0K | 1.26K | |
| Current assets | 500.6K | 5.28M | 210.9K | 360.6K | 421.9K |
| Property, plant and equipment | 12.2K | 941 | |||
| Total assets | 512.8K | 5.41M | 4.50M | 15.5M | 276.4M |
| Accounts payable | 582.2K | 1.48M | 933.0K | 508.0K | 419.0K |
| Current liabilities | 10.3M | 24.7M | 5.16M | 3.59M | 1.38M |
| Total debt | 1.44M | 5.12M | 16.1M | 16.5M | 90.0K |
| Total liabilities | 10.3M | 24.7M | 15.2M | 14.2M | 21.6M |
| Shareholders' equity | -9.81M | -19.3M | -10.7M | 1.29M | 254.9M |
| Shares outstanding | 27.1M | 17.5M | 160.3K | 688.6K | 690.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -9.96M | -1.45M | -3.35M | -869.0K | -1.22M |
| Capital spending | -13.1K | 0 | 0 | 0 | 0 |
| Free cash flow | -9.98M | -3.11M | -3.35M | -869.0K | -1.22M |
| Cash from investing | -788.1K | -2.85M | -819.0K | 264.0M | -276.0M |
| Cash from financing | 11.0M | 3.92M | -450.0K | 5.92M | 277.6M |
| Share buybacks | -1.80M | -10.7M | -700.0K | ||
| Change in cash | 281.3K | -378.1K | -4.61M | 5.05M | 336.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 16, 2026 | Explanation request | SEC |
| 8-K · Current report | Nov 3, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 22, 2026 | Big-stake notice | SEC |
All 111 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 14, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jul 13, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 6, 2026 | Acquisition or disposal | SEC |
| PRE 14A · Preliminary proxy statement | Jun 29, 2026 | Meeting notice | SEC |
| S-1 · Registration statement | Jun 23, 2026 | Offer document | SEC |
| D | Jun 18, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Jun 3, 2026 | Offer document | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 20, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 18, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Feb 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 17, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2026 | Other filings | SEC |
| S-1 · Registration statement | Feb 11, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 9, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 26, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Dec 31, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | Oct 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 15, 2025 | Insider trade | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Aug 14, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 11, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Jul 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 17, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 11, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Jul 3, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 3, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 27, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 27, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 26, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | Jun 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 30, 2025 | Quarterly report | SEC |
| 8-K/A · Current report, amended | May 30, 2025 | Acquisition or disposal | SEC |
| NT 10-Q · Late filing notice | May 15, 2025 | Explanation request | SEC |
| SCHEDULE 13D · Big-stake notice | May 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 6, 2025 | Acquisition or disposal | SEC |
| 3 · Initial statement of ownership | May 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 8-K12B | Apr 30, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 4, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jan 27, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 23, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jan 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 15, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 5, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Nov 8, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 12, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Aug 9, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 9, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Aug 9, 2024 | Offer document | SEC |
| S-4/A · Registration statement, amended | Aug 8, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Aug 7, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 5, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 25, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 11, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jun 14, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 4, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 8, 2023 | Other filings | SEC |
| S-4 · Registration statement | Nov 8, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 30, 2023 | Other filings | SEC |
| DRS · Draft registration statement | May 1, 2023 | Offer document | SEC |
Cap table
Built by 6ix from Liminatus Pharma, Inc.’s releases · as of Feb 17, 2026
- Common shares
- 1,343,207
- Fully diluted
- 1,343,207
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,343,207 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,343,207 |
| Aug 18, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nicholas Fernandez Other companies: JATT III Acquisition Corp (Director · Since at least Aug 25, 2026); Amanat Acquisition Corp (Chief Financial Officer · Since at least May 18, 2026); JATT II Acquisition Corp (Chief Financial Officer · Since at least Apr 16, 2026) | Director · Apr 30, 2025 – Apr 30, 2025 · Past |
| Beom Kyu Choi | Chief Technology Officer · Apr 30, 2025 – Apr 30, 2025 · Past |
| Byong Chul Yoo | Chief Science Officer · Apr 30, 2025 – Apr 30, 2025 · Past |
| Chris Kim | Chief Executive Officer, Director · Since at least Apr 30, 2025 |
| Chris Kim | CEO · Since at least Aug 24, 2026 |
| Eun Sook Lee | Director · Apr 30, 2025 – Apr 30, 2025 · Past |
| Ji Yeon Baek | Director · Apr 30, 2025 – Apr 30, 2025 · Past |
| Philip Wayne Lemons II | Director · Since at least Jul 10, 2025 |
| Richard JaiHwan Baek | Director · Since at least Jul 10, 2025 |
| Sang-Jin Lee | Head of Research & Development · Apr 30, 2025 – Apr 30, 2025 · Past |
All 11 people
| Person | Seat |
|---|---|
| Scott Dam | Chief Financial Officer · Apr 30, 2025 – Apr 30, 2025 · Past |
Log in to ask 6ix AI your own questions about Liminatus Pharma, Inc.